Haleon HLN
NYSE HLN
$9.90 +0.03 (+0.30%)
At close: Aug 20, 2026 · 2:48 PM UTC

Haleon (HLN) Net Income - Minority (2021 - 2022)

Haleon's (HLN) quarterly Net Income - Minority came in at -$33.2 million in Q3 2022, down 124.2% on a QoQ basis from -$14.8 million in Q4 2021.

Haleon (HLN) Net Income - Minority (2021 - 2022) Analysis & Trends

Haleon (HLN) has 2 years of Net Income - Minority data on file, last reported at -$33.2 million in Q3 2022.

  • Quarterly Net Income - Minority changed N/A year-over-year to -$33.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was -$33.2 million (changed N/A YoY) and the FY2021 annual result came in at -$15.1 million, changed N/A from the prior year.
  • Net Income - Minority fell to -$33.2 million in Q3 2022, from -$14.8 million in the prior quarter.
  • In the past five years, Net Income - Minority ranged from a high of -$14.8 million in Q4 2021 to a low of -$33.2 million in Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income - Minority (Qtr)
1 Haleon 43.94 Bn 42.97 Bn - -
2 Teva Pharmaceutical Industries 43.07 Bn 39.41 Bn 2.15 Bn -
3 Zoetis 31.50 Bn 29.83 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.59 Bn 22.79 Bn 5.10 Bn -
5 United Therapeutics 22.15 Bn 19.49 Bn 683.80 Mn -
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.53 Bn 15.14 Bn 935.80 Mn -
8 Elanco Animal Health 11.70 Bn 11.17 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.13 Bn 9.96 Bn - -
10 Alkermes 8.08 Bn 7.42 Bn 397.90 Mn -

Historic Data

Download Data
DateValue
Sep 20, 2022 -33.24 Mn
Dec 31, 2021 -14.83 Mn